Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Xenon Pharmaceuticals (Nasdaq: XENE) announced its participation in the upcoming 2025 RBC Capital Markets Global Healthcare Conference in New York. CEO Ian Mortimer will present a fireside chat on Wednesday, May 21, 2025, from 10:30-10:55 AM ET. The presentation will be available via webcast on Xenon's website.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE) ha annunciato la sua partecipazione alla prossima 2025 RBC Capital Markets Global Healthcare Conference a New York. Il CEO Ian Mortimer terrà una chiacchierata informale mercoledì 21 maggio 2025, dalle 10:30 alle 10:55 ET. La presentazione sarà disponibile in webcast sul sito web di Xenon.
Xenon è una società biofarmaceutica specializzata in neuroscienze che sviluppa prodotti per canali ionici per epilessia e depressione. Il loro candidato principale, azetukalner, è un apritore del canale potassio Kv7 in fase avanzata di sviluppo clinico per diverse indicazioni.
Xenon Pharmaceuticals (Nasdaq: XENE) anunció su participación en la próxima 2025 RBC Capital Markets Global Healthcare Conference en Nueva York. El CEO Ian Mortimer ofrecerá una charla informal el miércoles 21 de mayo de 2025, de 10:30 a 10:55 AM ET. La presentación estará disponible vía webcast en el sitio web de Xenon.
Xenon es una compañía biofarmacéutica centrada en neurociencias que desarrolla productos para canales iónicos para epilepsia y depresión. Su candidato principal, azetukalner, es un activador del canal de potasio Kv7 en etapa avanzada de desarrollo clínico para múltiples indicaciones.
Xenon Pharmaceuticals (나스닥: XENE)는 뉴욕에서 열리는 2025 RBC Capital Markets Global Healthcare Conference에 참가한다고 발표했습니다. CEO Ian Mortimer는 2025년 5월 21일 수요일 오전 10시 30분부터 10시 55분(동부시간)까지 파이어사이드 채팅을 진행할 예정입니다. 발표 내용은 Xenon 웹사이트를 통해 웹캐스트로 제공됩니다.
Xenon은 뇌과학에 중점을 둔 바이오제약 회사로, 간질과 우울증 치료를 위한 이온 채널 제품을 개발하고 있습니다. 주력 후보물질인 azetukalner는 다중 적응증을 대상으로 후기 임상 개발 중인 Kv7 칼륨 채널 개방제입니다.
Xenon Pharmaceuticals (Nasdaq : XENE) a annoncé sa participation à la prochaine 2025 RBC Capital Markets Global Healthcare Conference à New York. Le PDG Ian Mortimer animera une discussion informelle le mercredi 21 mai 2025, de 10h30 à 10h55 ET. La présentation sera disponible en webcast sur le site web de Xenon.
Xenon est une entreprise biopharmaceutique spécialisée en neurosciences, développant des produits ciblant les canaux ioniques pour l’épilepsie et la dépression. Leur principal candidat, azetukalner, est un activateur du canal potassique Kv7 en phase avancée de développement clinique pour plusieurs indications.
Xenon Pharmaceuticals (Nasdaq: XENE) gab seine Teilnahme an der bevorstehenden 2025 RBC Capital Markets Global Healthcare Conference in New York bekannt. CEO Ian Mortimer wird am Mittwoch, den 21. Mai 2025, von 10:30 bis 10:55 Uhr ET ein Fireside-Chat halten. Die Präsentation wird per Webcast auf der Webseite von Xenon verfügbar sein.
Xenon ist ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften, das Ionenkanal-Produkte für Epilepsie und Depression entwickelt. Ihr führender Kandidat, azetukalner, ist ein Kv7-Kaliumkanalöffner in der späten klinischen Entwicklungsphase für mehrere Indikationen.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025.
Fireside Chat Presentation Details:
Date: Wednesday, May 21, 2025
Time: 10:30-10:55 AM Eastern Time
Webcast: Register here
Presenter: Ian Mortimer, President and Chief Executive Officer
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When is Xenon Pharmaceuticals (XENE) presenting at the 2025 RBC Capital Markets Healthcare Conference?
Who will be presenting for Xenon Pharmaceuticals (XENE) at the RBC Healthcare Conference?
What is Xenon Pharmaceuticals' (XENE) lead drug candidate?
What therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?
